In a new video interview from AJMC, Miruna Sasu PhD, President and CEO of COTA Healthcare explains how real-world data (RWD) can empower the drug discovery and development processes. RWD can be used in tandem with wet-lab data to help propel drug candidate or biomarker identification. Once a promising candidate is identified, RWD and real-world evidence (RWE) can be used to organize clinical trials and recruit participants.
According to Sasu, “you can imagine in a dataset, you can say, “I want patients with X, Y, and Z, this type of tumor, so show me where those patients might be.” So, you’re looking on a map where those patients might be, and you choose the sites that we’re going to work with based on where those patients are. Instead of making those patients come to your sites, you can figure out which sites are getting the patients and go to them.”
To watch the video or read the transcript, click here.
(Source: AJMC, May 18th, 2022)
